Literature DB >> 29774626

Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.

Meritxell Carrió1, Bernat Gel1, Ernest Terribas1, Adriana Carolina Zucchiatti2, Teresa Moliné2, Inma Rosas1, Álex Teulé3, Santiago Ramón Y Cajal2, Juan Carlos López-Gutiérrez4, Ignacio Blanco5, Elisabeth Castellanos1, Conxi Lázaro3, Anat Stemmer-Rachamimov6, Cleofé Romagosa2, Eduard Serra1.   

Abstract

Plexiform neurofibromas (PNFs) are benign peripheral nerve sheath tumors involving large nerves present in 30%-50% Neurofibromatosis type 1 (NF1) patients. Atypical neurofibromas (ANF) are distinct nodular lesions with atypical features on histology that arise from PNFs. The risk and timeline of malignant transformation in ANF is difficult to assess. A recent NIH workshop has stratified ANFs and separated a subgroup with multiple atypical features and higher risk of malignant transformation termed atypical neurofibromatous neoplasms with uncertain biological potential (ANNUBP). We performed an analysis of intratumor heterogeneity on eight PNFs to link histological and genomic findings. Tumors were homogeneous although histological and molecular heterogeneity was identified. All tumors were 2n, almost mutation-free and had a clonal NF1(-/-) origin. Two ANFs from the same patient showed atypical features on histology and deletions of CDKN2A/B. One of the ANFs exhibited different areas in which the degree of histological atypia correlated with the heterozygous or homozygous loss of the CDKN2A/B loci. CDKN2A/B deletions in different areas originated independently. Results may indicate that loss of a single CDKN2A/B copy in NF1(-/-) cells is sufficient to start ANF development and that total inactivation of both copies of CDKN2A/B is necessary to form an ANNUBP.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ANNUNBP; CDKN2A; NF1; Neurofibromatosis type 1; atypical neurofibroma; plexiform neurofibroma

Mesh:

Substances:

Year:  2018        PMID: 29774626     DOI: 10.1002/humu.23552

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

Review 1.  Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.

Authors:  Lama Binobaid; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

2.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

3.  Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.

Authors:  Steven D Rhodes; Yongzheng He; Abbi Smith; Li Jiang; Qingbo Lu; Julie Mund; Xiaohong Li; Waylan Bessler; Shaomin Qian; William Dyer; George E Sandusky; Andrew E Horvai; Amy E Armstrong; D Wade Clapp
Journal:  Hum Mol Genet       Date:  2019-08-15       Impact factor: 6.150

Review 4.  Benign Peripheral Non-cranial Nerve Sheath Tumors of the Neck.

Authors:  Carlos Suárez; Fernando López; Juan P Rodrigo; William M Mendenhall; Remco de Bree; Antti A Mäkitie; Vincent Vander Poorten; Robert P Takes; Stefano Bondi; Luiz P Kowalski; Ashok R Shaha; Veronica Fernández-Alvarez; Julio C Gutiérrez; Nina Zidar; Carlos Chiesa-Estomba; Primoz Strojan; Alvaro Sanabria; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2022-06-11       Impact factor: 4.070

5.  Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.

Authors:  Charlie N Nelson; Eva Dombi; Jared S Rosenblum; Markku M Miettinen; Tanya J Lehky; Patricia O Whitcomb; Christina Hayes; Gretchen Scott; Sarah Benzo; Brigitte C Widemann; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2019-10-25       Impact factor: 5.115

6.  Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.

Authors:  Meritxell Carrió; Helena Mazuelas; Yvonne Richaud-Patin; Bernat Gel; Ernest Terribas; Imma Rosas; Senda Jimenez-Delgado; Josep Biayna; Leen Vendredy; Ignacio Blanco; Elisabeth Castellanos; Conxi Lázaro; Ángel Raya; Eduard Serra
Journal:  Stem Cell Reports       Date:  2019-01-31       Impact factor: 7.765

Review 7.  Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 2: vascular lesions, fibrohistiocytic tumors, muscle tumors, peripheral nerve sheath tumors, tumors of uncertain differentiation, and undifferentiated small round cell sarcomas.

Authors:  Ezekiel Maloney; Khalid Al-Dasuqi; Lina Irshaid; Annie Wang; Kimia Kani; Andrew Haims; Jack Porrino
Journal:  Skeletal Radiol       Date:  2021-07-23       Impact factor: 2.199

Review 8.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

Review 9.  New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

Authors:  Kyle B Williams; David A Largaespada
Journal:  Genes (Basel)       Date:  2020-04-28       Impact factor: 4.141

Review 10.  Translating current basic research into future therapies for neurofibromatosis type 1.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Lu Q Le
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.